Theravance Biopharma’s Merger Sale: Insider Liquidation Highlights Post‑Merger Strategy and Future Growth
Theravance’s merger with Zymeworks triggered a coordinated insider sell‑off—clarifying that the cash payouts are routine, not distress, and highlighting the new entity’s integration strategy and CVR impact.
3 minutes to read